BHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 95% based on the discounted cash flow analysis.
| Market cap | $2.41 Billion |
|---|---|
| Enterprise Value | $2.37 Billion |
| Dividend Yield | $1.28 (-) |
| Earnings per Share | $0.43 |
| Beta | 0.38 |
| Outstanding Shares | 375,000,000 |
| P/E Ratio | -2.18 |
|---|---|
| PEG | -2.94 |
| Price to Sales | 0.33 |
| Price to Book Ratio | -2.31 |
| Enterprise Value to Revenue | 0.3 |
| Enterprise Value to EBIT | 1.11 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | -0.49 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.3627▲ 44.27% |
|---|---|
| Total Calls | 3,863,700▲ 105.14% |
| Total Puts | 9,128,700▲ 152.45% |
Holdings and activity of institutional investors.
| Ownership % | 64.06%▲ 1.24% |
|---|---|
| Total Invested | $1.18B▼ 6.93% |
| Investors Holding | 241▼ 5.00% |
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...